Skip to Content
You are currently on the new version of our website. Access the old version .
Medical SciencesMedical Sciences
  • Article
  • Open Access

15 June 2026

17 Pages

Epidemiological Profile of Pediatric Patients with Acute Lymphoblastic Leukemia Admitted to Four Hospitals in Curitiba, Southern Brazil

,
,
,
,
,
,
,
,
…
1
Faculdades Pequeno Príncipe, Av. Iguaçu, 333, Rebouças, Curitiba CEP 80230-020, PR, Brazil
2
Instituto de Pesquisa Pelé Pequeno Príncipe, Av. Silva Jardim, 1632, Água Verde, Curitiba CEP 80250-060, PR, Brazil
3
Laboratório Central do Estado do Paraná (LACEN-PR), R. Sebastiana Santana Fraga, 1395, Guatupê, São José dos Pinhais CEP 83060-500, PR, Brazil
*
Author to whom correspondence should be addressed.

Abstract

Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Understanding its epidemiological characteristics is essential for guiding public health strategies. In this study, we characterized the epidemiological profiles that may contribute to the risk of ALL in children in southern Brazil. Methods: Clinical and epidemiological data from 71 children (1–15 years old) admitted and newly diagnosed with ALL at four hospitals in Curitiba, Paraná, Brazil, were retrieved and analyzed. Results: Among the 71 children with ALL, the majority were male (n = 43, 60.6%), with an age range of 1–3 years (n = 26, 36.6%), self-identified as White (n = 47, 66.2%), and were born in Paraná state (n = 61, 85.9%). Nearly half had a family history of cancer (n = 33, 46.5%), primarily among grandparents (n = 36, 61%). Parental environmental exposures included smoking (n = 30, 42.3%) and occupational exposure to chemicals or radiation (n = 17, 23.9%). At diagnosis, most patients (n = 43, 60.5%) had a bone marrow blast count > 70%, and 27 patients (38%) had a peripheral blood blast count > 70%. B-cell ALL was the predominant subtype (n = 61, 85.9%). In B-cell ALL cases, the most frequent molecular subtype was high hyperdiploidy (n = 17, 23.9%). White blood cell counts differed significantly between the B-cell ALL and T-cell ALL groups (p = 0.029). Conclusions: Our findings provide insights into ALL epidemiology in southern Brazil and highlight regional differences across the country.

1. Introduction

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer worldwide, representing approximately 25% of all pediatric malignancies [1]. It involves uncontrolled proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs, requiring prompt diagnosis and treatment [2]. ALL occurs predominantly in children aged 2–5 years, with fewer cases in infants and adolescents, and is more frequent in males [2]. Although chemotherapy has improved survival rates, it carries risks, including infections, organ toxicity, and long-term side effects [3,4]. The identification of prognostic factors like age at diagnosis, white blood cell (WBC) count, genetic alterations, and initial therapy response is crucial for treatment planning [5].
In 2021, 46,304 cases of ALL were reported in children globally, representing a 14% decrease from 1990 [2]. The National Cancer Institute reported 40 cases per million children aged 0–14 years in the United States [5]. In a Brazilian study encompassing 16 population-based cancer registries, the age-adjusted median incidence rate of leukemia among children aged 0–14 years was 53.3 cases per million, with no significant sex differences at 3 years of age [6]. The incidence of childhood leukemia in Brazil showed regional variation from 1997 to 2004 [6], with the population having unique characteristics due to interethnic relationships [7]. A study in Piaui, northeast Brazil, reported that 93.56% of childhood leukemia hospitalizations were among mixed-race individuals [8]. Most studies on pediatric ALL in Brazil have been conducted in the southeast and northeast regions. Although the exact cause is often unknown, ALL development is associated with genetic, environmental, or preexisting conditions [9].
Brazil is an expansive and highly heterogeneous country with substantial regional differences in sociodemographic and environmental factors, which may influence the epidemiological profile of cancers, such as ALL [10]. Therefore, findings from a single region may not be generalizable to the entire country. In this context, to contribute to the understanding of ALL in Brazil, we aimed to characterize the sociodemographic, epidemiological, clinical, and laboratory profiles, as well as environmental and occupational factors, of children with ALL admitted to four hospitals in Curitiba, Paraná, southern Brazil.

2. Methods

2.1. Participants

Between May 2021 and February 2024, families of 84 children newly diagnosed with ALL and admitted to four hospitals in Curitiba, Paraná, Brazil, were invited to participate in an ongoing project titled “Searching for Markers of Therapeutic Response in Acute Lymphoblastic Leukemia (ALL): Monitoring Variations in Gene Expression and Enteric Microbiome in Pediatric Patients with ALL Throughout Chemotherapy Treatment.” The inclusion criteria were pediatric patients aged 1–15 years, newly diagnosed with ALL, and without syndromes predisposing to ALL, such as Down syndrome or Fanconi anemia. Children diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) or T-cell acute lymphoblastic leukemia (T-ALL) were included. Participants who withdrew at any stage of the study were excluded.
The participating institutions and number of invitations extended were as follows: Hospital Pequeno Príncipe (HPP; May 2021–February 2024, 45 invitations), Hospital Erasto Gaertner (HEG; December 2021–February 2024, 32 invitations), Complexo Hospital de Clínicas da Universidade Federal do Paraná (CHC/UFPR; March 2022–February 2024, 1 invitation), and Hospital Universitário Evangélico Mackenzie (HUEM; June 2022–February 2024, 6 invitations). This project was approved by the Research Ethics Committees of the four participating hospitals under the Certificate of Presentation for Ethical Consideration numbers: 21767019.0.0000.0097 (HPP), 21767019.0.3001.0098 (HEG), 21767019.0.3002.0096 (CHC/UFPR), and 21767019.0.3004.0103 (HUEM). Informed consent and/or assent were obtained from all participants. None of the patients had a history of primary immunodeficiency. Additionally, none of the patients received prior treatment with cytotoxic or radioactive agents or immunotherapy.

2.2. Data Collection and Statistical Analysis

Patients were diagnosed with B-ALL or T-ALL by the clinical staff at each participating hospital, based on clinical and laboratory findings, including leukocyte morphology, immunophenotyping, cytogenetics, and molecular genetics. Similarly, the treatment protocol—comprising the Recife Protocol for ALL (RE-LLA) [11], the Berlin–Frankfurt–Münster protocol (BFM) [12], and the 2021 Protocol of the Brazilian Cooperative Group for the Treatment of Childhood Acute Lymphoblastic Leukemia (GBTLI), an ongoing multicenter Brazilian protocol—was determined by the medical team at each hospital according to the institutional criteria. Sociodemographic, epidemiological, clinical, and laboratory data were collected from the medical records and from a survey conducted with the parents or legal guardians of the participants at the time of inclusion. Based on the WBC counts in peripheral blood at diagnosis, patients were classified into three categories: >100,000 cells/mm3, referred to as hyperleukocytosis [13]; 50,000–100,000 cells/mm3 (values > 50,000 cells/mm3 are considered a risk factor in some treatment protocols) [11]; and <50,000 cells/mm3.
Statistical analyses were exploratory and descriptive, focusing on bivariate associations between categorical variables without aiming to establish causality or estimate independent effects. Owing to the small sample sizes and sparse contingency tables, Fisher’s exact test was used to ensure robust and accurate inference. For quantitative data (age and WBC counts), groups were compared using the Mann–Whitney test. Further, because of the limited number of T-ALL cases, subgroup comparisons were considered exploratory and should be interpreted with caution. Analyses were performed using GraphPad Prism software, version 8.0.1.

3. Results

Of the 84 eligible participants, 11 refused to participate and 2 withdrew after obtaining initial consent; therefore, a total of 71 pediatric patients with ALL were evaluated (Figure 1). The sociodemographic, epidemiological, clinical, and laboratory characteristics of the participants are summarized in Table 1 and Figure 2.
Figure 1. A flow diagram of a multicenter cohort of pediatric acute lymphoblastic leukemia (ALL) patients across four hospitals. Abbreviation: ALL, acute lymphoblastic leukemia. Colors represent different hospitals.
Table 1. Sociodemographic and epidemiological characteristics of children with acute lymphoblastic leukemia admitted to four Hospitals in Curitiba, Paraná.
Figure 2. A summary of the main findings of pediatric patients with acute lymphoblastic leukemia in southern Brazil. Distribution of patients with ALL according to hospital, sex, ethnicity, parental environmental exposure, age at diagnosis, and ALL type. The map shows the geographic distribution of cases across immediate geographic regions. Abbreviations: ALL, acute lymphoblastic leukemia; HPP, Hospital Pequeno Príncipe; HEG, Hospital Erasto Gaertner; HUEM, Hospital Universitário Evangélico Mackenzie; CHC/UFPR, Complexo Hospital de Clínicas da Universidade Federal do Paraná; IntRG, intermediate region; IntRG-01, Curitiba region; IntRG-02, Guarapuava region; IntRG-03, Cascavel region; IntRG-04, Maringá region; IntRG-05, Londrina region; IntRG-06, Ponta Grossa region.
Among the 71 pediatric patients, 61 (85.9%) had B-ALL, and 10 (14.1%) had T-ALL. Most children with ALL were male (n = 43, 60.6%), with no significant sex differences between the B-ALL and T-ALL groups (p = 0.296). Most patients were aged 1–3 years (n = 26, 36.6%), followed by 4–6 years (n = 20, 28.2%), 7–9 years (n = 12, 16.9%), 10–12 years (n = 10, 14.1%), and 13–15 years (n = 3, 4.2%) (Table 1). Overall, almost half of the patients (n = 34, 47.9%) were aged between 1 and 4 years (Figure 3). No significant differences in age distribution were observed between the B-ALL and T-ALL groups. The patients’ age varied from 1 to 14 years (mean: 5.46 ± 3.55 years, median: 5 years). Patients with B-ALL had a mean age of 5.31 ± 3.63 years and median age of 4 years. Among those with T-ALL, the maximum age was 10 years, mean age was 6.4 ± 3.03 years, and median age was 7 years. No significant difference in age was observed between the patients with B-ALL and those with T-ALL (p = 0.2506).
Figure 3. Age histogram of children with T-cell acute lymphoblastic leukemia and B-cell acute lymphoblastic leukemia admitted to four Hospitals in Curitiba, Paraná. Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia.
The majority of patients self-identified as White (n = 47, 66.2%); most children were eutrophic (n = 40, 56.4%) and born at full term (n = 57, 80.3%). No significant differences in ALL subtypes were observed when comparing White versus non-White patients, eutrophic versus non-eutrophic status, and full-term versus non–full-term births. Cesarean section was the most common delivery method, observed in 49 cases (69.0%), and 40 children (56.3%) did not receive exclusive breastfeeding during the first 6 months of life.
Most patients were born in Paraná state (61/71, 85.9%), of which 43 (70.5%) were born in the intermediate geographical region of Curitiba and 28 (65.1%) in Curitiba city (Figure 4A). The status of the patients’ residences was also assessed. Most patients (39/71, 54.9%) remained at their birth residences, whereas 42.3% (30/71) moved (Figure 4B). Among those who moved within the state of Paraná, only one changed the geographic region. The state of Paraná and its intermediate geographical regions, along with the birthplace of each patient, are shown in Figure 5.
Figure 4. Distribution of demographics, cancer history in relatives, and environmental/ occupational exposure characteristics among patients with T-cell acute lymphoblastic leukemia and those with B-cell acute lymphoblastic leukemia. (A). Intermediate region of birth. (B). Intermediate region of residence. (C). Type of cancer in relatives. (D). Degree of kinship with affected relatives. (E). Parental smoking. (F). Parental occupational exposure to chemicals or radiation. Data are presented as percentages for each acute leukemia subtype. Additional information regarding these results is provided in Supplemental Table S1. Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia.
Figure 5. Geographical distribution of patients’ birthplaces. Map of Brazil highlighting the state of Paraná and its six intermediate geographic regions, with black dots indicating the place of birth of each patient. Abbreviations: IntRG, intermediate region; IntRG-01, Curitiba region; IntRG-02, Guarapuava region; IntRG-03, Cascavel region; IntRG-04, Maringá region; IntRG-05, Londrina region; IntRG-06, Ponta Grossa region. This figure is based on the intermediate geographic regional division of Paraná, as defined by Instituto Brasileiro de Geografia e Estatística—IBGE [16].
Approximately 50% of the children with ALL (n = 33, 46.5%) reported having at least one relative with a history of cancer. In total, 59 cases of cancer in the family were reported by the parents or legal guardians of the participants. Fifteen (25.4%) children with ALL had at least two cases of cancer in the family. Among those with a family history, 39 (66.1%) reported cancer in the direct line of kinship and 20 (33.9%) in the collateral line, with no significant difference between the B-ALL and T-ALL groups (p = 0.703). Considering the degree of kinship, most reported cases of cancer occurred in grandparents of children with ALL (36, 61.0%), followed by cases in aunts/uncles (14, 23.7%). The main types of cancer in the family of children with ALL were hematological (n = 8, 13.6%) and urological (n = 8, 13.6%). Additional information on family cancer history is shown in Figure 4C,D.
Regarding environmental and occupational factors, parental occupational exposure to chemicals or radiation was reported in 17 (23.9%) patients, whereas 30 (42.3%) reported exposure to tobacco smoke. In both cases, no significant differences were observed between the leukemia subtypes (p = 0.696 and p > 0.99, respectively). Additional information on parental exposure to chemicals/radiation or parental smoking is shown in Figure 4E and 4F, respectively.
Medical records of children with ALL were analyzed to extract information about clinical findings, including organomegaly, lymphadenopathy or skin lesions, involvement of the central nervous system (CNS) and testis, blast percentages at diagnosis in peripheral blood and bone marrow, and molecular testing. The findings are presented in Table 2.
Table 2. Clinical and laboratory data of children with acute lymphoblastic leukemia.
Most children with ALL were admitted to HPP (n = 41, 57.7%), followed by HEG (n = 23, 32.4%), HUEM (n = 6, 8.5%), and CHC/UFPR (n = 1, 1.4%). Regarding healthcare coverage, 48 patients (67.6%) were admitted under the Brazilian public health system and 23 (32.4%) under private health insurance. Among clinical findings, organomegaly was observed in 22 (31.0%) patients with ALL, lymphadenopathy in 19 (26.8%) patients, and skin lesions in 4 (5.6%) patients. No significant difference in these findings was observed between the B-ALL and T-ALL groups (p > 0.05). CNS and testicular involvement were identified in 5 (7.0%) and 1 (2.3%) patients, respectively, with no significant difference between the ALL subtypes. At diagnosis, 43 (60.5%) children with ALL had ≥70% blasts in the bone marrow, and 27 (38%) had ≥70% blasts in peripheral blood; however, no significant difference was observed between the B-ALL and T-ALL groups.
At diagnosis, most children (n = 59, 83.1%) had a peripheral WBC count of <50,000 cells/mm3, and 12 (16.9%) had counts ≥ 50,000 cells/mm3. The distribution of WBC counts varied significantly across ALL subtypes, with higher WBC counts observed in children with T-ALL than in those with B-ALL (p = 0.029). WBC counts varied from 1450 to 686,600 cells/mm3 (mean: 50,062 ± 118,756 cells/mm3, median: 8130 cells/mm3). B-ALL patients had a mean of 36,244 ± 102,110 cells/mm3 and a median of 7010 (1520–686,600) cells/mm3. WBC count was significantly higher in T-ALL patients, who had a mean of 134,351 ± 176,050 cells/mm3 and a median of 44,085 (1450–508,460) cells/mm3 (p = 0.0304).
Among children with B-ALL, molecular subtyping was not otherwise specified in 29 (40.8%) cases. Nevertheless, high hyperdiploidy (HHD) was present in 17 (23.9%) cases, followed by ETV6::RUNX1 fusion in 12 (16.9%) cases. Less frequent molecular subtypes included TCF3::PBX1 fusion (n = 2, 2.8%) and BCR::ABL1 fusion (n = 1, 1.4%). Regarding ALL treatment protocols, most patients (n = 40, 56.3%) were assigned to the Brazilian Childhood Cooperative Group for Treatment of ALL in Children 2021 protocol, an ongoing Brazilian multicenter research protocol in which HPP and HEG are participating centers. This was followed by assignment to the Recife Protocol for ALL [11] (n = 20, 28.2%) and Berlin–Frankfurt–Münster protocol [12] (n = 11, 15.5%). Each patient’s protocol assignment was determined by the medical team of the hospital to which they were admitted according to the institutional criteria.

4. Discussion

ALL is the most common childhood malignancy and a significant public health concern in the pediatric population of Brazil. Considering Brazil’s continental size and regional disparities, it is essential to understand the epidemiological and clinical features of ALL in different regions. However, most studies on pediatric ALL have focused on the southeast and northeast regions, followed by the south region. In this study, we present the clinical and epidemiological findings of children diagnosed with ALL in Curitiba, Paraná, Brazil.
According to the National Cancer Institute, from 2017 to 2020, 42 cases of lymphoid leukemia were reported in Paraná in children aged 1–14 years (23 boys and 19 girls) in population-based cancer registries [17]. This number may be underestimated owing to the limitations of data collection [18]. Among the 71 pediatric patients with ALL, 14.1% had T-ALL, a proportion similar to that observed worldwide [19,20,21]. In other Brazilian studies, T-ALL accounted for 8–25% of childhood ALL cases [22,23,24].
Male sex was more prevalent in our cohort (60.6%), consistent with findings reported in Brazilian [8,22,23,25,26] and international [2,27,28,29,30] studies. In our study, the majority of admissions occurred in children aged 1–4 years, whereas in other regions of Brazil, the peak incidence of ALL was observed in patients aged 2–5 years [24,31,32] and between 0 and 4 years worldwide [33,34]. Regarding ethnicity, 66.2% of our patients self-identified as White, which is consistent with the findings of another study conducted in southern Brazil [35]. In contrast, a study from northeast Brazil reported a different ethnic profile, with 93.6% of patients self-identifying as mixed race [8], which may reflect regional demographic variations within Brazil. Additionally, 21% of our patients (n = 15) were obese; obesity has been associated with poor survival outcomes [36].
As expected, most patients in our study were born in the state of Paraná, considering that the hospitals were located in Curitiba, the state capital. Paraná has 24 high-complexity cancer treatment centers distributed across 15 municipalities [37]. Additionally, these institutions receive pediatric patients from outside the state [17,37]. The high number of patients from HPP may reflect the longer recruitment period at this site (33 months) than at other hospitals (HEG, 27 months; HUEM, 20 months; CHC/UFPR, 24 months). Additionally, most patients (48, 67.6%) in this study were managed within the public health network Sistema Único de Saúde (Brazilian Unified Health System), which refers patients to hospitals according to regionalized care guidelines [38].
Our study showed that most patients underwent full-term delivery, with cesarean section being the most frequent procedure. In Brazil, this procedure is common, and the proportion found in our study reflects the national pattern [39]. More than half of the patients (56.3%) were not exclusively breastfed until 6 months of age. Breastfeeding, especially for ≥6 months, is associated with a low risk of ALL. It provides nutritional support, maternal antibodies, anti-inflammatory molecules, and beneficial microbes that support the infant gut microbiome, potentially modulating the immune system [40,41,42].
Almost half of the patients reported at least one case of cancer in their family, mainly among second-degree relatives (grandparents), with hematological and urological cancers being the most frequently reported in our cohort. Hematological malignancies in first- or second-degree relatives are associated with a slightly increased risk of childhood ALL [43], and other studies have reported associations with specific cancers in first-degree relatives, including testicular cancer in fathers [44], as well as esophageal, breast, prostate, connective tissue cancers, and leukemia [45]. However, some studies found no significant associations [46,47]. Overall, these findings suggest that the role of family history of cancer in childhood ALL remains controversial, highlighting the complexity of its interpretation in pediatric patients.
Parental occupational exposure to radiation and/or chemicals was reported by almost a quarter of the legal guardians of 17 (23.9%) children with ALL in our cohort. Chemicals are well-established risk factors for cancer, and hydrocarbons are of particular concern because of their widespread use in household and industrial products [48]. In our study, the most frequent parental occupational exposures were paints or varnishes (9.8%) and organic solvents (including petroleum and its derivatives) (8.5%). Exposure to pesticides, fertilizers, other agricultural products (2.8%), chlorine compounds (2.8%), and ionizing radiation (1.4%) was also reported. Associations between parental exposure to paints and pigments and childhood ALL have been previously reported [48]. Household paint exposure increases the risk of childhood ALL, particularly when it occurs shortly before conception, during pregnancy, or after birth [49,50]. In pooled analyses of 12 international case–control studies, paternal occupational pesticide exposure around conception increased the risk of childhood ALL by approximately 20%, whereas the results for maternal exposure showed inconsistent findings [50,51,52,53,54]. Only ionizing radiation has been associated with childhood ALL, and maternal exposure to X-rays during pregnancy increases the risk of leukemia in the offspring by approximately 50% [48,55,56]. Regarding parental smoking, epidemiological evidence has shown no association between maternal smoking and the risk of childhood ALL and only a weak association between paternal smoking and the risk of childhood ALL [9,57,58,59].
Physical examination at diagnosis revealed organomegaly (31.8%) and lymphadenopathy (26.9%) in children with ALL. In a study from Pakistan [60], almost 65% of children diagnosed with ALL had physical abnormalities, including hepatomegaly and splenomegaly. Similarly, in Mexico [61], organomegaly was reported in >60% of cases. Similar findings were observed in Ceará, northeastern Brazil [25]. Organomegaly and lymphadenopathy are common in pediatric patients with ALL, although their prevalence varies regionally. Skin manifestations were observed in 4 (5.6%) children with ALL in our study, which typically indicates advanced disease with extramedullary infiltration and is often associated with a poor prognosis [62]. In our study, 5 (7.0%) children with ALL were diagnosed with CNS involvement, a condition that can be detected in 3–20% of patients [33,63,64]. Although effective treatment options are available, CNS involvement at diagnosis remains a major challenge in the management of pediatric ALL. Intensive CNS-directed treatment is nonspecific and associated with the risks of neurotoxicity, relapse, and long-term neurocognitive sequelae [65,66].
At diagnosis, a total of 12 (16.9%) children had a WBC count >50,000 cells/mm3, of which 8 (11.3%) had hyperleukocytosis (>100,000 cells/mm3). In Rio de Janeiro, southeast Brazil, Bonilha et al. found that 38.7% of children with ALL had WBC counts >50,000 cells/mm at diagnosis, and 20.4% of them had hyperleukocytosis [22]. Similarly, in Bahia, northeast Brazil, 25.6% of patients had WBC counts >50,000 cells/mm at diagnosis, of which half (12.8%) had hyperleukocytosis [23]. Children with hyperleukocytosis at ALL diagnosis were previously observed, varying from 11.2% [67] to 22.5% [68] in Europe. An elevated WBC count at diagnosis is associated with poor prognosis in children with ALL [69]. In this study, although a significant difference was observed in the WBC counts between patients with B-ALL and those with T-ALL, it should be interpreted with caution because of the limited number of T-ALL cases. Half of the children with T-ALL (n = 5, 50%) had elevated WBC counts, and 40% had counts >100,000 cells/mm3. Similar findings regarding elevated WBC counts in patients with T-ALL have been reported in Poland [70]. In the study, the authors also observed a correlation between high WBC count at diagnosis and high incidence of infection as a complication of ALL therapy. Most epidemiological studies on childhood ALL, particularly in Brazil, do not stratify clinical or laboratory variables by immunophenotype, thereby limiting the detailed comparisons.
Among patients with B-ALL, HHD (23.9%) was the most frequent molecular subtype, followed by ETV6::RUNX1 (16.9%). These are the most common subtypes in children with B-ALL worldwide, with HHD and ETV6::RUNX1 frequencies varying from 15% to 40% and from 13% to 34%, respectively [19,33,34]. In previous studies in Brazil [22,23], a low frequency of HHD was observed (3–6%), but a large proportion of patients in those studies had no cytogenetic results available, whereas in this study, karyotyping results were available for 70% of patients with B-ALL. In a study conducted in Rio de Janeiro [22], BCR::ABL1 was the most frequently detected subtype (15.4%). This gene fusion is usually observed in 2–8% of pediatric B-ALL cases [34,45] and was observed in only one patient in the present study and in another Brazilian study [23].
This study has some limitations. First, the absence of a control group prevented comparisons between environmental exposures and other potential risk factors. Second, the relatively small number of patients may have limited the generalizability of our findings. Finally, the information was collected only at the time of diagnosis, which may have restricted the assessment of exposure and clinical characteristics over time.

5. Conclusions

This multicenter study describes the demographic, clinical, and environmental characteristics of pediatric patients with ALL from four hospitals in Curitiba, southern Brazil. The cohort was characterized by a predominance of male patients, diagnosis at an early age (1–4 years), and B-ALL subtype. Parental reports indicated environmental exposures, with tobacco use being the most frequently mentioned. In addition, nearly half of the patients had a family history of cancer, mainly among second-degree relatives, with hematological and urological malignancies being the most commonly reported. These findings highlight the importance of broader nationwide data collection and further studies to improve the understanding of childhood ALL and to support public health strategies tailored to regional contexts.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/medsci14020318/s1. Table S1: Detailed data underlying Figure 4. Legend: Information is organized into four worksheets containing distributions of patients according to (1) intermediate geographic region at birth and of residence, (2) family history of cancer by degree of kinship, (3) parental tobacco exposure, and (4) parental occupational exposure.

Author Contributions

Conceptualization: L.M.D.-C., R.R. and L.B., Methodology: R.N.S., L.A.d.O., S.C.L.-A., T.M.V., L.S.R., D.K., A.C.S., R.R., L.M.D.-C. and L.B., Data curation: R.N.S., L.A.d.O., S.C.L.-A., T.M.V., L.S.R., D.K., A.C.S., R.R., L.M.D.-C. and L.B., Investigation: R.N.S., L.A.d.O., T.M.V., L.S.R., R.R., L.M.D.-C. and L.B., Validation: R.N.S., L.A.d.O., Curitiba Transcriptomics and Microbiomics ALL Consortium, and L.B., Formal Analysis: R.N.S., L.A.d.O. and L.B., Supervision: L.B., Funding acquisition: L.A.d.O., R.R. and L.M.D.-C., Writing—original draft: R.N.S., L.A.d.O., S.C.L.-A., T.M.V., R.R., L.M.D.-C. and L.B., Writing—review & editing: R.N.S., L.A.d.O., S.C.L.-A., T.M.V., L.S.R., D.K., A.C.S., R.R., L.M.D.-C., Curitiba Transcriptomics and Microbiomics ALL Consortium and L.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Programa Nacional de Apoio à Atenção Oncológica (PRONON) of the Brazilian Ministry of Health (25000.043593/2018-67), and financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil—Finance Code 001. This research received partial financial support from a project approved by Conselho Estadual dos Direitos da Criança e do Adolescente (CEDCA), funded through tax incentive programs, via Fundo Estadual para Infância e Adolescência (FIA-PR), from Paraná, Brazil.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committees of the four participating hospitals under the Certificate of Presentation for Ethical Consideration numbers: 21767019.0.0000.0097 (HPP, 17 October 2019), 21767019.0.3001.0098 (HEG, 20 October 2021), 21767019.0.3002.0096 (CHC/UFPR, 6 October 2021), and 21767019.0.3004.0103 (HUEM, 11 May 2022).

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical reasons.

Acknowledgments

We express our sincere gratitude to the families and children who voluntarily participated in this study. We also thank the Instituto de Pesquisa Pelé Pequeno Príncipe. Curitiba Transcriptomics and Microbiomics ALL Consortium: The consortium comprises Edna K. Carbone, Alejandra A C. de Castro, Gabriela C. F. L. Canali, Hadelle H. Hassmann, Camile C. Vicentini, Ana P. Kuczynski, Mara A. D. Pianovski, Taís T. Barros, Robson de C. Coelho, Mariane F. Caleffi, Maria L. L. C. Brito, Rhayane P. de O. da Silva, Adriano L. G. de Lima, Tiago H. Tormen, Leniza C. L. Lichtvan, Marcela Q. Amaral, Fabiana R. da Silva, Débora S. Carmo, Ana P. de O. S. de Queiroz from the participating hospitals.

Conflicts of Interest

The authors declare that they have no competing interests.

Abbreviations

ALLAcute lymphoblastic leukemia
HPPHospital Pequeno Príncipe
HEGHospital Erasto Gaertner
CHC/UFPRComplexo Hospital de Clínicas da Universidade Federal do Paraná
HUEMHospital Universitário Evangélico Mackenzie
B-ALLB-cell acute lymphoblastic leukemia
T-ALLT-cell acute lymphoblastic leukemia
CNSCentral nervous system
HHDHigh hyperdiploidy
INCAInstituto Nacional de Câncer
IBGEInstituto Brasileiro de Geografia e Estatística
WBCWhite blood cell
PCRPolymerase chain reaction
FISHFluorescent in situ hybridization

References

  1. Bhojwani, D.; Yang, J.J.; Pui, C.H. Biology of childhood acute lymphoblastic leukemia. Pediatr. Clin. N. Am. 2015, 62, 47–60. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  2. Hu, Y.; Liu, Y.; Fu, J.; Liu, Y.; Wang, H.; Song, Y. Global, Regional, and National Burden of Acute Lymphoblastic Leukemia in Children: Epidemiological Trends Analysis from 1990 to 2021. iScience 2024, 27, 111356. [Google Scholar] [CrossRef] [Scilit]
  3. Anand, U.; Dey, A.; Chandel, A.K.S.; Sanyal, R.; Mishra, A.; Pandey, D.K.; De Falco, V.; Upadhyay, A.; Kandimalla, R.; Chaudhary, A.; et al. Cancer Chemotherapy and Beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics. Genes Dis. 2023, 10, 1367–1401. [Google Scholar] [CrossRef] [Scilit]
  4. Schmiegelow, K.; Müller, K.; Mogensen, S.S.; Mogensen, P.R.; Wolthers, B.O.; Stoltze, U.K.; Tuckuviene, R.; Frandsen, T. Non-Infectious Chemotherapy-Associated Acute Toxicities During Childhood Acute Lymphoblastic Leukemia Therapy. F1000Research 2017, 6, 444. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Acute Lymphoblastic Leukemia Treatment; National Cancer Institute: Bethesda, MD, USA, 2025. Available online: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq (accessed on 25 July 2025).
  6. de Souza Reis, R., Sr.; de Camargo, B.; de Oliveira Santos, M.; de Oliveira, J.M.; Azevedo Silva, F.; Pombo-de-Oliveira, M.S. Childhood Leukemia Incidence in Brazil According to Different Geographical Regions. Pediatr. Blood Cancer 2011, 56, 58–64. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. de Oliveira, M.S.P.; Koifman, S.; Vasconcelos, G.M.; Emerenciano, M.; de Oliveira Novaes, C. Brazilian Collaborative Study Group of Infant Acute Leukemia. Development and Perspective of Current Brazilian Studies on the Epidemiology of Childhood Leukemia. Blood Cells Mol. Dis. 2009, 42, 121–125. [Google Scholar] [CrossRef] [Scilit]
  8. Leite, I.G.C.; Monteiro, V.C.D.M.; Moreira, D.R.; Moura, L.C.D.; Azevedo, P.S.d.S. Epidemiological Profile of Leukemia in Children and Adolescents in the State of Piauí, from 2014 to 2024 (Perfil Epidemiológico De Leucemia Em Crianças E Adolescentes No Estado Do Piauí, De 2014 a 2024). Rev. Ft 2025, 29, 9–10. [Google Scholar] [CrossRef] [Scilit]
  9. Schmidt, J.A.; Hornhardt, S.; Erdmann, F.; Sánchez-García, I.; Fischer, U.; Schüz, J.; Ziegelberger, G. Risk Factors for Childhood Leukemia: Radiation and Beyond. Front. Public Health 2021, 9, 805757. [Google Scholar] [CrossRef] [Scilit]
  10. Jardim, B.C.; Junger, W.L.; Daumas, R.P.; e Silva, G.A. Estimation of cancer incidence in Brazil and its regions in 2018: Methodological aspects. Cad. Saúde Pública 2024, 40, 1–16. [Google Scholar] [CrossRef] [Scilit]
  11. Pedrosa, F.; Coustan-Smith, E.; Zhou, Y.; Cheng, C.; Pedrosa, A.; Lins, M.M.; Pedrosa, M.; Lucena-Silva, N.; Ramos, A.M.D.L.; Vinhas, E.; et al. Reduced–Dose Intensity Therapy for Pediatric Lymphoblastic Leukemia: Long-Term Results of the Recife RELLA05 Pilot Study. Blood 2020, 135, 1458–1466. [Google Scholar] [CrossRef] [Scilit]
  12. Campbell, M.; Kiss, C.; Zimmermann, M.; Riccheri, C.; Kowalczyk, J.; Felice, M.S.; Kuzmanovic, M.; Kovacs, G.; Kosmidis, H.; Gonzalez, A.; et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. J. Clin. Oncol. 2023, 41, 3499–3511. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Giammarco, S.; Chiusolo, P.; Piccirillo, N.; Di Giovanni, A.; Metafuni, E.; Laurenti, L.; Pagano, L. Hyperleukocytosis and leukostasis: Management of a medical emergency. Expert. Rev. Hematol. 2017, 10, 147–154. [Google Scholar] [CrossRef] [Scilit]
  14. Petruccelli, J.L.; Saboia, A.L. Características Étnico-raciais da População: Classificações e identidades. In Estudos e Análises: Informação Demográfica e Socioeconômica, Número 2; Instituto Brasileiro de Geografia e Estatística (IBGE): Rio de Janeiro, Brazil, 2013. Available online: https://biblioteca.ibge.gov.br/visualizacao/livros/liv63405.pdf (accessed on 25 July 2025).
  15. World Health Organization. WHO Child Growth Standards: Growth Velocity Based on Weight, Length and Head Circumference: Methods and Development; World Health Organization: Geneva, Switzerland, 2009; Available online: https://iris.who.int/server/api/core/bitstreams/908e8634-2471-4139-bdff-8edaadc813a2/content (accessed on 4 May 2026).
  16. Instituto Brasileiro de Geografia e Estatística (IBGE). Divisão Regional do Brasil em Regiões Geográficas Imediatas e Regiões Geográficas Intermediárias Coordenação de Geografia; IBGE: Rio de Janeiro, Brazil, 2017. Available online: https://biblioteca.ibge.gov.br/visualizacao/livros/liv100600.pdf (accessed on 4 May 2026).
  17. Instituto Nacional de Câncer–INCA. Região Sul—Instituto Nacional de Câncer—INCA. 2022. Available online: https://www.gov.br/inca/pt-br/assuntos/cancer/tratamento/onde-tratar-pelo-sus/regiao-sul (accessed on 4 May 2026).
  18. Pena, G.P.M.; Santos, A.T.C.D.; Pezzotti, C.M.; Lima, C.A.; Daniel, C.B.; Laporte, C.A.; Veneziano, D.B.; Souza, D.L.B.D.; Carvalho, F.N.D.; Alencar, H.F.D.; et al. Registros de Câncer de Base Populacional no Brasil: Relevância, Desafios e Oportunidades. Rev. Bras. Cancerol. 2025, 71, 1–13. [Google Scholar] [CrossRef] [Scilit]
  19. Vrooman, L.M.; Silverman, L.B. Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr. Hematol. Malig. Rep. 2016, 11, 385–394. [Google Scholar] [CrossRef] [Scilit]
  20. Bardelli, V.; Arniani, S.; Pierini, V.; Di Giacomo, D.; Pierini, T.; Gorello, P.; Mecucci, C.; La Starza, R. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Genes 2021, 12, 1118. [Google Scholar] [CrossRef] [Scilit]
  21. Tran, T.H.; Hunger, S.P. The Genomic Landscape of Pediatric Acute Lymphoblastic Leukemia and Precision Medicine Opportunities. Semin. Cancer Biol. 2022, 84, 144–152. [Google Scholar] [CrossRef] [Scilit]
  22. Bonilha, T.A.; Obadia, D.D.; Valveson, A.C.; Land, M.G. Outcome of Childhood Acute Lymphoblastic Leukemia Treatment in a Single Center in Brazil: A Survival Analysis Study. Cancer Rep. 2022, 5, e1452. [Google Scholar] [CrossRef] [Scilit]
  23. Correa, B.T.; Silva, G.S.S.; Mendes, W.J.S.; Maia, A.D.M.; Aleluia, A.C.M.; Fonseca, T.C.C.; da Guarda, C.C.; Gonçalves, M.D.S.; Aleluia, M.M. Association of the Clinical Profile and Overall Survival of Pediatric Patients With Acute Lymphoblastic Leukemia. Front. Pediatr. 2023, 11, 1223889. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Santos, M.M.D.; Santos, A.S.D.; Santos, H.H.D.M.; Santos, L.D.S.; Nascimento, R.J.M.; Torres, A.J.L. Immunophenotypic Characterization of Acute Leukemias in Bahia, Brazil. Einstein 2023, 21, eAO0117. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Sousa, D.W.L.; de Almeida Ferreira, F.V.; Félix, F.H.C.; de Oliveira Lopes, M.V. Acute Lymphoblastic Leukemia in Children and Adolescents: Prognostic Factors and Analysis of Survival. Rev. Bras. Hematol. Hemoter. 2015, 37, 223–229. [Google Scholar] [CrossRef] [Scilit]
  26. Souza, B.R.S.; Barbosa, C.L.; Cajado, D.C.S.; Rezende, G.O. Acute lymphoblastic leukemia in children: Advances in diagnosis, treatment, and epidemiological aspects in the state of Amazonas (Leucemia linfoblástica aguda em crianças, avanços no diagnóstico, tratamento e os aspectos epidemiológicos no estado do Amazonas). Rev. Ft 2024, 29, 54–55. [Google Scholar] [CrossRef] [Scilit]
  27. Abdelmabood, S.; Fouda, A.E.; Boujettif, F.; Mansour, A. Treatment Outcomes of Children with Acute Lymphoblastic Leukemia in a Middle-Income Developing Country: High Mortalities, Early Relapses, and Poor Survival. J. Pediatr. (Rio J.) 2020, 96, 108–116. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Cueva-Arica, D. Results of treatment protocols for childhood acute lymphoblastic leukemia in a Peruvian hospital (Resultados de dos protocolos de tratamiento para la leucemia linfoide aguda infantil en un hospital peruano). Rev. Hematol. 2024, 28, 48–57. [Google Scholar] [CrossRef] [Scilit]
  29. Gupta, S.; Dai, Y.; Chen, Z.; Winestone, L.E.; Teachey, D.T.; Bona, K.; Aplenc, R.; Rabin, K.R.; Zweidler-McKay, P.; Carroll, A.J. Racial and Ethnic Disparities in Childhood and Young Adult Acute Lymphocytic Leukaemia: Secondary Analyses of Eight Children’s Oncology Group Cohort Trials. Lancet Haematol. 2023, 10, e129–e141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Pasha, F.; Urbančič, D.; Maxhuni, R.; Krasniqi, S.; Grajçevci Uka, V.; Mlinarič-Raščan, I. Prevalence and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in Kosovo. Cancers 2024, 16, 1988. [Google Scholar] [CrossRef] [Scilit]
  31. Azevedo-Silva, F.; Camargo, B.D.; Pombo-de-Oliveira, M.S. Implications of Infectious Diseases and the Adrenal Hypothesis for the Etiology of Childhood Acute Lymphoblastic Leukemia. Braz. J. Med. Biol. Res. 2010, 43, 226–229. [Google Scholar] [CrossRef] [Scilit]
  32. de Souza, P.C.F.; Espinosa, M.M.; Teixeira, M.T.B.; Galvão, N.D.; de Lima, F.C.S. Staging at Diagnosis and Survival of Hematologic Neoplasms in Children and Adolescents in Mato Grosso, Brazil: A Population-based Study. Asian Pac. J. Cancer Prev. 2025, 26, 171–179. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Barragan, F.A.; Mills, L.J.; Raduski, A.R.; Marcotte, E.L.; Grinde, K.E.; Spector, L.G.; Williams, L.A. Genetic Ancestry, Differential Gene Expression, and Survival in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancer Med. 2023, 12, 4761–4772. [Google Scholar] [CrossRef] [Scilit]
  34. Sun, Y.; Long, S.; Liu, W. Observation of the Molecular Genetics Among Children With Acute Lymphoblastic Leukemia: A Retrospective Study Based on the SEER Database. Medicine 2020, 99, e20009. [Google Scholar] [CrossRef] [Scilit]
  35. Ibagy, A.; Silva, D.B.; Seiben, J.; Winneshoffer, A.P.; Costa, T.E.; Dacoregio, J.S.; Costa, I.; Faraco, D. Acute Lymphoblastic Leukemia in Infants: 20 Years of Experience. J. Pediatr. (Rio J.) 2013, 89, 64–69. [Google Scholar] [CrossRef] [Scilit]
  36. Dong, L.; Dai, G.; Zhao, J. Impact of Body Mass Index at Diagnosis on Outcomes of Pediatric Acute Leukemia: A Systematic Review and Meta-Analysis. PLoS ONE 2024, 19, e0302879. [Google Scholar] [CrossRef] [Scilit]
  37. Secretaria da Saúde do Paraná (SESA). Paraná has 24 Hospitals in 15 Cities Providing Cancer Treatment Through the SUS (Brazilian Public Health System) (Paraná tem 24 Hospitais em 15 Cidades para o Tratamento Contra o Câncer no SUS). 2025. Available online: https://www.saude.pr.gov.br/Noticia/Parana-tem-24-hospitais-em-15-cidades-para-o-tratamento-contra-o-cancer-no-SUS (accessed on 4 May 2026).
  38. Legislação Informatizada—LEI N° 8.080, De 19 De Setembro De 1990—Publicação Original. 1990. Available online: https://www2.camara.leg.br/legin/fed/lei/1990/lei-8080-19-setembro-1990-365093-publicacaooriginal-1-pl.html (accessed on 4 May 2026).
  39. Braga, A.; Sun, S.Y.; Zaconeta, A.C.M.; Junior, A.T.; Luz, A.G.; Osanan, G.; Duarte, G.; Ramos, J.G.L.; Wender, M.C.O.; Nomura, R.M.Y.; et al. Increase in Cesarean Sections in Brazil—A Call to Reflection. Rev. Bras. Ginecol. Obstet. 2023, 45, 109–112. [Google Scholar] [CrossRef]
  40. Greaves, M. A Causal Mechanism for Childhood Acute Lymphoblastic Leukaemia. Nat. Rev. Cancer 2018, 18, 471–484. [Google Scholar] [CrossRef] [Scilit]
  41. Søegaard, S.H.; Andersen, M.M.; Rostgaard, K.; Davidsson, O.B.; Olsen, S.F.; Schmiegelow, K.; Hjalgrim, H. Exclusive Breastfeeding Duration and Risk of Childhood Cancers. JAMA Netw. Open 2024, 7, e243115. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Yang, Y.; Yu, C.; Fu, R.; Xia, S.; Ni, H.; He, Y.; Zhu, K.; Sun, Q. Association of Cesarean Section With Risk of Childhood Leukemia: A Meta-Analysis From An Observational Study. Hematol. Oncol. 2023, 41, 182–191. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Infante-Rivard, C.; Guiguet, M. Family History of Hematopoietic and Other Cancers in Children With Acute Lymphoblastic Leukemia. Cancer Detect. Prev. 2004, 28, 83–87. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Couto, E.; Chen, B.; Hemminki, K. Association of Childhood Acute Lymphoblastic Leukaemia With Cancers in Family Members. Br. J. Cancer 2005, 93, 1307–1309. [Google Scholar] [CrossRef] [Scilit]
  45. Li, X.; Sundquist, K.; Sundquist, J.; Försti, A.; Hemminki, K. Family History of Early Onset Acute Lymphoblastic Leukemia is Suggesting Genetic Associations. Sci. Rep. 2021, 11, 12730. [Google Scholar] [CrossRef] [Scilit]
  46. Perrillat, F.; Clavel, J.; Jaussent, I.; Baruchel, A.; Leverger, G.; Nelken, B.; Philippe, N.; Schaison, G.; Sommelet, D.; Vilmer, E.; et al. Family Cancer History and Risk of Childhood Acute Leukemia (France). Cancer Causes Control 2001, 12, 935–941. [Google Scholar] [CrossRef] [Scilit]
  47. Zierhut, H.; Linet, M.S.; Robison, L.L.; Severson, R.K.; Spector, L. Family History of Cancer and Non-Malignant Diseases and Risk of Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Cancer Epidemiol. 2012, 36, 45–51. [Google Scholar] [CrossRef] [Scilit]
  48. Belson, M.; Kingsley, B.; Holmes, A. Risk factors for acute leukemia in children: A review. Environ. Health Perspect. 2007, 115, 138–145, Erratum in Env. Health Perspect 2010, 118, A380. PMID: 17366834; PMCID: PMC1817663. [Google Scholar] [CrossRef] [Scilit]
  49. Bailey, H.D.; Milne, E.; de Klerk, N.H.; Fritschi, L.; Attia, J.; Cole, C.; Armstrong, B.K.; Aus-ALL Consortium. Exposure to House Painting and the Use of Floor Treatments and the Risk of Childhood Acute Lymphoblastic Leukemia. Int. J. Cancer 2011, 128, 2405–2414. [Google Scholar] [CrossRef] [Scilit]
  50. Bailey, H.D.; Metayer, C.; Milne, E.; Petridou, E.T.; Infante-Rivard, C.; Spector, L.G.; Clavel, J.; Dockerty, J.D.; Zhang, L.; Armstrong, B.K.; et al. Home Paint Exposures and Risk of Childhood Acute Lymphoblastic Leukemia: Findings From the Childhood Leukemia International Consortium. Cancer Causes Control. 2015, 26, 1257–1270. [Google Scholar] [CrossRef] [Scilit]
  51. Ferreira, J.D.; Couto, A.C.; Pombo-de-Oliveira, M.S.; Koifman, S. Brazilian Collaborative Study Group of Infant Acute Leukemia. In Utero Pesticide Exposure and Leukemia in Brazilian Children <2 Years of Age. Environ. Health Perspect. 2013, 121, 269–275. [Google Scholar] [CrossRef] [Scilit]
  52. Glass, D.C.; Reid, A.; Bailey, H.D.; Milne, E.; Fritschi, L. Risk of Childhood Acute Lymphoblastic Leukaemia Following Parental Occupational Exposure to Pesticides. Occup. Environ. Med. 2012, 69, 846–849. [Google Scholar] [CrossRef] [Scilit]
  53. Van Maele-Fabry, G.; Lantin, A.C.; Hoet, P.; Lison, D. Childhood Leukaemia and Parental Occupational Exposure to Pesticides: A Systematic Review and Meta-analysis. Cancer Causes Control 2010, 21, 787–809. [Google Scholar] [CrossRef] [Scilit]
  54. Wigle, D.T.; Turner, M.C.; Krewski, D. A Systematic Review and Meta-Analysis of Childhood Leukemia and Parental Occupational Pesticide Exposure. Environ. Health Perspect. 2009, 117, 1505–1513. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Pereira, F.A.C.; Mirra, A.P.; Latorre, M.R.D.O.; Assunção, J.V. Environmental risk factors and acute lymphoblastic leukemia in childhood (Fatores de risco ambientais e leucemia linfoblástica aguda na infância). Rev. Cienc. Salud 2017, 15, 129–144. [Google Scholar] [CrossRef] [Scilit]
  56. Finch, S.C. Radiation-Induced Leukemia: Lessons from History. Best Pract. Res. Clin. Haematol. 2007, 20, 109–118. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Klimentopoulou, A.; Antonopoulos, C.N.; Papadopoulou, C.; Kanavidis, P.; Tourvas, A.D.; Polychronopoulou, S.; Baka, M.; Athanasiadou-Piperopoulou, F.; Kalmanti, M.; Sidi, V. Maternal Smoking During Pregnancy and Risk for Childhood Leukemia: A Nationwide Case-Control Study in Greece and Meta-Analysis. Pediatr. Blood Cancer 2012, 58, 344–351. [Google Scholar] [CrossRef] [Scilit]
  58. Liu, R.; Zhang, L.; McHale, C.M.; Hammond, S.K. Paternal Smoking and Risk of Childhood Acute Lymphoblastic Leukemia: Systematic Review and Meta-Analysis. J. Oncol. 2011, 2011, 854584. [Google Scholar] [CrossRef] [Scilit]
  59. Schüz, J.; Erdmann, F. Environmental Exposure and Risk of Childhood Leukemia: An Overview. Arch. Med. Res. 2016, 47, 607–614. [Google Scholar] [CrossRef] [Scilit]
  60. Fadoo, Z.; Nisar, I.; Yousuf, F.; Lakhani, L.S.; Ashraf, S.; Imam, U.; Zaheer, J.; Naqvi, A.; Belgaumi, A. Clinical Features and Induction Outcome of Childhood Acute Lymphoblastic Leukemia in a Lower/Middle Income Population: A Multi-Institutional Report From Pakistan. Pediatr. Blood Cancer 2015, 62, 1700–1708. [Google Scholar] [CrossRef] [Scilit]
  61. Jaime-Pérez, J.C.; García-Arellano, G.; Herrera-Garza, J.L.; Marfil-Rivera, L.J.; Gómez-Almaguer, D. Revisiting the Complete Blood Count and Clinical Findings at Diagnosis of Childhood Acute Lymphoblastic Leukemia: 10-Year Experience at a Single Center. Hematol. Transfus. Cell Ther. 2019, 41, 57–61. [Google Scholar] [CrossRef] [Scilit]
  62. Robak, E.; Braun, M.; Robak, T. Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment. Cancers 2023, 15, 5393. [Google Scholar] [CrossRef] [Scilit]
  63. Lenk, L.; Alsadeq, A.; Schewe, D.M. Involvement of the Central Nervous System in Acute Lymphoblastic Leukemia: Opinions on Molecular Mechanisms and Clinical Implications Based on Recent Data. Cancer Metastasis Rev. 2020, 39, 173–187. [Google Scholar] [CrossRef] [Scilit]
  64. Miconi, C.; Maître, E.; Allouche, S.; Brunel, V.; Bera, E.; Buchonnet, G.; Deparis, M.; Schneider, P.; Rouger, J. Acute leukemia in children: Evaluating the necessity of routine biochemical analysis of cerebrospinal fluid. Eur. J. Pediatr. 2025, 184, 148. [Google Scholar] [CrossRef] [Scilit]
  65. McNeer, J.L.; Schmiegelow, K. Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia. Curr. Hematol. Malig. Rep. 2022, 17, 1–14. [Google Scholar] [CrossRef] [Scilit]
  66. Thastrup, M.; Duguid, A.; Mirian, C.; Schmiegelow, K.; Halsey, C. Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia: Challenges and Solutions. Leukemia 2022, 36, 2751–2768. [Google Scholar] [CrossRef] [Scilit]
  67. Stary, J.; Zimmermann, M.; Campbell, M.; Castillo, L.; Dibar, E.; Donska, S.; Gonzalez, A.; Izraeli, S.; Janic, D.; Jazbec, J.; et al. Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002. J. Clin. Oncol. 2014, 32, 174–184. [Google Scholar] [CrossRef] [Scilit]
  68. Testi, A.M.; Attarbaschi, A.; Valsecchi, M.G.; Möricke, A.; Cario, G.; Niggli, F.; Silvestri, D.; Bader, P.; Kuhlen, M.; Parasole, R.; et al. Outcome of Adolescent Patients With Acute Lymphoblastic Leukaemia Aged 10–14 Years as Compared With Those Aged 15–17 Years: Long-Term Results of 1094 Patients of the AIEOP-BFM ALL 2000 Study. Eur. J. Cancer 2019, 122, 61–71. [Google Scholar] [CrossRef] [Scilit]
  69. Kakaje, A.; Alhalabi, M.M.; Ghareeb, A.; Karam, B.; Mansour, B.; Zahra, B.; Hamdan, O. Rates and Trends of Childhood Acute Lymphoblastic Leukaemia: An Epidemiology Study. Sci. Rep. 2020, 10, 6756. [Google Scholar] [CrossRef] [Scilit]
  70. Mitura-Lesiuk, M.M.; Dubaj, M.; Dembowska, A.; Bigosiński, K.; Raniewicz, M. Hyperleukocytosis in Pediatric Patients With Acute Lymphoblastic Leukemia: Demographic and Clinical Characteristics. J. Clin. Med. 2024, 13, 5185. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.